2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2175 UCHL1 promotes MYC signaling, BCMA expression, and proteostasis in high-risk multiple myeloma

Johnathan Altom, Cooper Bastian2, Akshaya Radhakrishnan3, Sumedha Kommuru4, Alessandro La Ferlita5, Francesca Cottini, MD6
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 The Ohio State University, Columbus, Ohio, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States

Background: Multiple myeloma (MM) is an incurable hematologic malignancy caused by the uncontrolled proliferation of malignant plasma cells within the bone marrow. MM cells are heavily reliant on strict protein quality control and MYC oncogenic activity for survival and proliferation. Ubiquitin c-terminal hydrolase 1 (UCHL1) is a deubiquitinating enzyme (DUB), which removes ubiquitin from target proteins, preserving their stability. In this study, we investigated the role of UCHL1 in MM cell survival, proteostasis, and signaling and evaluated the therapeutic effects of UCHL1 inhibition using in vitro and in vivo models of MM.

Methods: UCHL1 expression was assessed in the MMRF CoMMpass dataset and correlated with cytogenetic abnormalities and outcomes. Human MM cell lines (OPM-2, MM.1S, H929, RPMI-8226, KMS-11, and U266) were evaluated for UCHL1 mRNA and protein levels. U266 cells were used for UCHL1 overexpression studies and MM.1S and OPM-2 for UCHL1 silencing experiments. The same panel of MM cells, as well as patient-derived samples from patients with MM or plasma cell leukemia, were treated with UCHL1-targeting compound, 6RK73. RNA-sequencing, quantitative proteomics and ubiquitinomics were performed in MM cells treated with 6RK73. Cell viability was assessed by flow cytometry and MTS assay; BCMA expression was evaluated by flow cytometry under different experimental conditions. Finally, MM.1S xenograft models in NSG mice were used to determine the antitumor activity of 6RK73 in vivo.

Results: We first evaluated UCHL1 mRNA expression in patients using the CoMMpass database. UCHL1 expression was elevated in high-risk cytogenetic groups of MM, specifically those with t(4;14) and gain/amplification of chromosome 1q, t(4;14) co-occurring with chromosome 1p deletion, and TP53 deletions or mutations. Moreover, higher UCHL1 expression was associated with inferior overall survival. Forced expression of UCHL1 in U266 cells promoted cellular growth, whereas UCHL1 depletion in MM.1S and OPM-2 cells using three independent shRNAs increased cell death and reduced cellular proliferation. Consistently, treatment with 6RK73 for 48 hours induced greater cytotoxicity in UCHL1-high MM.1S, OPM-2, and KMS-11 cells (IC50 range, 1.1–1.5 μM) than in UCHL1-low cell lines (IC50 range, 4.3–5.3 μM).

To define the molecular functions of UCHL1 in MM, we performed RNA-sequencing and mass-spectrometry-based proteomic and ubiquitinomic analyses in OPM-2 cells treated with 6RK73. Gene set enrichment analysis demonstrated suppression of MYC target genes, with concomitant reduction of IRF4 (interferon regulatory factor 4) and BCMA (B cell maturation antigen). Ubiquitinomics revealed increased ubiquitination of MYC following UCHL1 inhibition, which was confirmed by ubiquitin immunoprecipitation. Similarly, UCHL1 depletion by shRNA in MM.1S and OPM-2 cells decreased MYC, IRF4 and BCMA expression, as confirmed by quantitative PCR, western blot analysis, and flow cytometry. Since BCMA activates NF-κB signaling, we next examined this pathway and observed that UCHL1 inhibition decreased levels of NFKB2 and RelB, together with reduced NFKB2 activation following stimulation with the BCMA ligand APRIL.

Pathways associated with the unfolded protein response and protein homeostasis in MM were also significantly altered following UCHL1 inhibition. Genomic and pharmacological inhibition of UCHL1 decreased XBP1 (X-box binding protein 1) mRNA and protein levels while increasing CHOP (C/EBP homologous protein) expression, consistent with disruption of proteostasis and induction of terminal apoptosis. Accordingly, 6RK73 synergistically reduced MM cell viability when combined with proteasome inhibitors. Finally, treatment with 6RK73 significantly reduced tumor burden in a MM xenograft model compared with vehicle-treated controls. Ongoing studies are evaluating additional dosing regimens and combination strategies.

Conclusions: Our findings identify UCHL1 as a regulator of MM cell survival that integrates MYC signaling with protein homeostasis. UCHL1 inhibition increases MYC ubiquitination, suppresses the MYC-IRF4 axis and BCMA/NF-κB signaling, and disrupts the unfolded protein response, resulting in MM cell death. The preferential activity of UCHL1 inhibition in UCHL1-high MM cells, its synergy with proteasome inhibitors, and its antitumor activity in vivo support UCHL1 as a potential therapeutic target in MM, particularly in high-risk disease.

Johnathan Altom: No relevant conflicts of interest to declare.